Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics

Despite controversy about the efficacy and safety of aducanumab, the FDA’s fast-tracking of this medicine is truly historic. However, structural problems leading to socioeconomic disparities and systemic racism in science, healthcare, and society have left out under-represented populations. This per...

Descripción completa

Detalles Bibliográficos
Autores principales: Padala, Sanjana P., Yarns, Brandon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277694/
https://www.ncbi.nlm.nih.gov/pubmed/35891635
http://dx.doi.org/10.3233/ADR-220023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277694/
https://www.ncbi.nlm.nih.gov/pubmed/35891635
http://dx.doi.org/10.3233/ADR-220023

Ejemplares similares